Mannose-P-dolichol utilisation defect 1 (Q89996): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Created a new Item
 
‎Changed label, description and/or aliases in pt-br, en
description / pt-brdescription / pt-br
 
As síndromes CDG (distúrbios congênitos de glicosilação) são um grupo de doenças autossômicas recessivas que afetam a síntese de glicoproteínas. O tipo de síndrome CDG se caracteriza por retardo psicomotor, convulsões, deficiência de crescimento e anomalias cutâneas e oculares. Foi descrito em quatro crianças. A síndrome é causada por mutações no gene MPDU1, localizado na região p13.1-p12 do cromossomo 17.
description / endescription / en
 
The CDG (Congenital Disorders of Glycosylation) syndromes are a group of autosomal recessive disorders affecting glycoprotein synthesis. CDG syndrome type If is characterised by psychomotor delay, seizures, failure to thrive, and cutaneous and ocular anomalies. It has been described in four children. The syndrome is caused by mutations in the MPDU1 gene, localised to the p13.1-p12 region of chromosome 17.

Revision as of 16:55, 15 August 2026

The CDG (Congenital Disorders of Glycosylation) syndromes are a group of autosomal recessive disorders affecting glycoprotein synthesis. CDG syndrome type If is characterised by psychomotor delay, seizures, failure to thrive, and cutaneous and ocular anomalies. It has been described in four children. The syndrome is caused by mutations in the MPDU1 gene, localised to the p13.1-p12 region of chromosome 17.
Language Label Description Also known as
default for all languages
ID_2086182172
    English
    Mannose-P-dolichol utilisation defect 1
    The CDG (Congenital Disorders of Glycosylation) syndromes are a group of autosomal recessive disorders affecting glycoprotein synthesis. CDG syndrome type If is characterised by psychomotor delay, seizures, failure to thrive, and cutaneous and ocular anomalies. It has been described in four children. The syndrome is caused by mutations in the MPDU1 gene, localised to the p13.1-p12 region of chromosome 17.

      Statements